UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2013

Commission File Number: 001-34563

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

18/F, Tower A, Global Trade Center 36 North Third Ring Road East, Dongcheng District Beijing 100013 People's Republic of China (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes 🗆 No 🗵

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

TABLE OF CONTENTS



-

TABLE OF CONTENTS

Exhibit 99.1 – Press release: Concord Medical Reports First Quarter 2013 Financial Results

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

By: /s/ Jianyu Yang

Name: Jianyu Yang

Title: Chairman and Chief Executive Officer

Date: May 22, 2013

Concord Medical Reports First Quarter 2013 Financial Results

BEIJING, May 21, 2013 /PRNewswire-Asia-FirstCall/ — Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China and the parent of Chang'an Hospital, today reported its unaudited consolidated financial results for the first quarter ended March 31, 2013^[1].

First Quarter 2013 Highlights

- **Total net revenue,** which consists of net revenues generated from the network business and hospital business, was RMB203.9 million (\$32.8 million) in the first quarter of 2013, a 91.1% increase from RMB106.7 million in the first quarter of 2012.
- Gross profit in the first quarter of 2013 was RMB71.5 million (\$11.5 million), a 14.8% increase from RMB62.3 million in the first quarter of 2012.
- Net income attributable to ordinary shareholders in the first quarter of 2013 was RMB19.7 million (\$3.2 million), an 18.6% decrease from RMB24.2 million in the first quarter of 2012.
- Basic and diluted earnings per American depositary share ("ADS")^[2] in the first quarter of 2013 were RMB0.44 (\$0.07).
- Adjusted EBITDA^[3] (non-GAAP) in the first quarter of 2013 was RMB89.0 million (\$14.3 million), a 21.0% increase from RMB73.6 million in the first quarter of 2012.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, stated, "I am pleased with the financial results of first quarter of 2013, especially the strong revenue growth, healthy gross profit and Adjusted EBITDA compared with the first quarter of 2012. During the quarter, we benefited from the continuously increasing demand from the general population for high-quality and affordable healthcare services. We saw a positive momentum in patient number growth in both our network and hospital businesses."

"Since 2012, we have increased our investment in the telemedicine and web business units. In telemedicine, we are building a network based on data transmission and storage technology that will enable doctors and physicists in our network to more easily communicate and consult with each other on cases. We are also setting up telemedicine centers in hospitals in remote areas so that the doctors there can benefit from the knowledge and expertise of other doctors in the CCM network. We have also invested in web-based and mobile marketing business units that will helped our centers targeting new patients more effectively. We believe that these new business units will bring incremental future revenues to the company. We plan to continue investing in these business units."

"Based on our estimates of the business environment and progress so far in 2013, we are confident that we will achieve the 2013 revenue targets of RMB930 million to RMB975 million issued in the first quarter."

"On May 15, 2013, we announced the signing of a \$50 million loan package with International Finance Corporation ("IFC"). We will use the loan to expand our network of radiotherapy centers in China as well as to build the planned specialty hospitals in Beijing and Guangzhou. These hospitals represent crucial components of our growth strategy to create a nationwide network of oncology centers and specialty hospitals, providing high-quality radiotherapy services to all of our patients in China."

"We plan to start construction of our specialty cancer hospital in Guangzhou during the second half of 2013. Also, we have made progress towards obtaining the necessary administrative approvals related to the Beijing hospital project, in cooperation with Sino-Japanese Friendship Hospital. Once both hospitals are open, they will provide high-end radiotherapy services, based on international standard of quality assurance and planning."

Recent Developments

IFC loan Agreement – On May 15, 2013, the Company announced that it had signed a US\$50 million loan package agreement with IFC, a member of the World Bank Group focusing on private sector development in emerging markets.

Share repurchase program – On October 9, 2012, the Company announced that its board of directors has approved the extension of its share repurchase program originally approved by the board of directors on September 30, 2011. During the first quarter of 2013, the Company repurchased 105,067 ADSs, representing 315,201 ordinary shares for a total \$0.4 million, including commissions.

Through March 31, 2013, the Company has repurchased 2,293,808 ADSs, representing 6,881,424 ordinary shares, in the open market, for a total consideration of \$8,068,225 (including commissions) under the share repurchase program. As of March 31, 2013, the Company had 18.9 million ADSs outstanding, representing 56.7 million ordinary shares.

First quarter 2013 results by segment

Network business

The Company added one radiotherapy center in the first quarter of 2013, bringing the total number of centers in operation to 137 in 54 cities in China as of March 31, 2013. As of the same date, the Company had entered into agreements to establish 11 additional centers.

Net revenues from the network business were RMB111.7 million (\$18.0 million) for the first quarter of 2013, representing an increase of 4.6% from the first quarter of 2012, primarily due to increase in number of patients in our existing centers as well as contribution from the new centers opened during 2012.

Gross profit margin of the network business was 55.4% for the first quarter of 2013, as compared with 58.4% for the first quarter of 2012. The lower gross profit margin was primarily due to increased compensation and operating cost at our centers.

Capital expenditure of the network business was RMB33.8 million (\$5.4 million) for the first quarter of 2013, compared with RMB36.0 million in the first quarter of 2012.

Selling expenses in the network business were RMB16.5 million (\$2.7 million) for the first quarter of 2013, representing an increase of 106% from the first quarter of 2012. The increase was mainly due to selling expenses relating to our telemedicine and web business of RMB4.5 million (\$0.7 million). The Company also incurred higher marketing and promotion expenses relating to newly opened centers.

General and administrative expenses in the network business were RMB20.8 million (\$3.4 million), representing an increase of 22.9% from the first quarter of 2012. The increase was mainly due to general and administrative expenses relating to the telemedicine and web business of RMB2.1 million (\$0.3 million).

Accounts receivable from the network business was RMB185.9 million (\$29.9 million) as of March 31, 2013, as compared to RMB168.3 million as of December 31, 2012. The average period of sales outstanding for accounts receivable, or Days Sales Outstanding (DSO) was 155 days for the first quarter of 2013, as compared to 153 days for the fourth quarter of 2012.

As of March 31, 2013, the Company, not including Chang'an Hospital, had bank credit lines of RMB2,217 million (\$357.1 million), of which RMB912.0 million (\$146.8 million) was utilized.

During the first quarter of 2013, the Company handled 7,517 patient treatment cases and 71,084 patient diagnostic cases in the center network, representing a 4.4% decrease and 59.6% increase from the first quarter of 2012, respectively.

Hospital business

.

Financial results of Chang'an Hospital were consolidated into our results of operations since the third quarter of 2012 after we consummated the acquisition of 52% equity interest in Chang'an Hospital. Net revenues from the hospital business were RMB92.3 million (\$14.9 million) for the first quarter of 2013, which consisted of:

- outpatient revenues of RMB18.4 million (\$3.0 million), representing 20% of the net revenues from the hospital business;
- inpatient revenues of RMB34.1 million (\$5.5 million), representing 37% of the net revenues from the hospital business; and
- medicine revenues of RMB39.8 million (\$6.4 million), representing 43% of the net revenues from the hospital business.

Cost of service for the hospital business for the first quarter of 2013 was RMB82.6 million (\$13.3 million), of which the medicine cost was RMB33.9 million (\$5.5 million) and the medical service cost was RMB48.7 million (\$7.8 million).

Gross profit margin of the hospital business was 10.5% for the first quarter of 2013.

Capital expenditure of the hospital business was RMB9.8 million (\$1.6 million) for the first quarter of 2013.

General and administrative expenses in the hospital business were RMB4.6 million (\$0.7 million).

As of March 31, 2013, Chang'an Hospital had accounts receivable of RMB30.8 million (\$5.0 million), representing days sales outstanding of 36 days, as compared to 34 days for the fourth quarter of 2012. The accounts receivable was mainly from medical revenues covered by various government-sponsored insurance programs. Chang'an Hospital settles the balance with the local social insurance bureau on a periodic basis.

Chang'an Hospital received 117,773 outpatients and 7,530 inpatients for the first quarter of 2013. The average bed utilization for the quarter was 89.2%. The average days of hospital stay was 10.0 days per patient for the quarter. Chang'an Hospital operated 1,015 beds as of March 31, 2013.

Chang'an Hospital is a leading private-owned, general service, for-profit hospital, located in Xi'an, Shanxi Province. Established in 2002, Chang'an Hospital had 57 departments with over 1,250 medical and non-medical staff as of March 31, 2013.

2013 Outlook

Based on current market and operating conditions, estimated business expansion and forecasted Chang'an Hospital financial results, Concord Medical expects to generate total net revenues in an estimated range of RMB930 million to RMB975 million in 2013, which would represent a 40% to 47% increase from 2012. The revenues from network business and hospital business as percentages to total revenues are expected to be approximately 55% and 45% in 2013, respectively. Finally, the Company is targeting to start construction of the specialty cancer oncology hospital in Guangzhou in 2013.

These estimates are based on current market and operating conditions, are subject to change, and may be impacted positively or negatively by factors outside the Company's control, including but not limited to macroeconomic events in the markets in which the Company operates. See "Safe Harbor Statement" below for additional information regarding forward-looking statements.

Conference Call Information

Concord Medical's management will hold an earnings conference call at 8:00 a.m. Eastern Daylight Time on May 22, 2013 (8:00 p.m. Beijing/Hong Kong time on May 22, 2013).

Dial-in details for the earnings conference call are as follows:

U.S. Toll Free: 1-866-519-4004 U.K. Toll Free: 08082346646 International: 65 67239381 China Toll Free: 400-620-8038 / 800-819-0121 Hong Kong Toll Free: 800-930-346 Passcode: CCM

A replay of the conference call may be accessed by phone at the following numbers for 7 days:

U.S. Toll Free: 1-855-452-5696 International: +61 2 8199 0299 Conference ID: 71197242

Additionally, a live and archived webcast of this conference call will be available at http://ir.concordmedical.com/.

About Concord Medical

Concord Medical Services Holdings Limited operates the largest network of radiotherapy and diagnostic imaging centers in China, measured by revenues and the number of centers in operation and is the parent of Chang'an Hospital. As of March 31, 2013, the Company operated a network of 137 centers with 77 hospital partners that spanned 54 cities and 24 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com.

Safe Harbor Statement

This news release may contain "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging; and possible effects on consumers and hospitals, hospital construction, and suppliers, as a result of inflation and the Chinese government's policies and actions to control inflation. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The Company does not assume any obligation to update any forward-looking statement, except as required by law.

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense. The Company believes excluding share-based compensation expense from its GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results, as such expense is not directly attributable to the underlying performance of the Company's business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expense are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of Adjusted EBITDA, which is defined in this announcement as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses, and other adjustments. Other adjustments include foreign exchange losses and other expense income. Furthermore, Adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the

For more information, please contact:

Concord Medical Services Mr. Adam J. Sun (Chinese and English) +86 10 5957 5266 adam.sun@concordmedical.com

Mr. Ting Jia (Chinese and English) +86 10 5903 6688 (ext. 809) ting.jia@concordmedical.com

Ms. Gloria Huang (Chinese and English) +86 10 5903 6688 (ext. 639) gloria.huang@concordmedical.com

Solebury Communications

In China: Ms. Vickie Zhao <u>CCM@soleburyir.com</u> (+86) 10 6563-0288 (ext. 801)

In the United States: Mr. Richard Zubek <u>rzubek@soleburyir.com</u> (+1) 203-428-3231

[1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.2108 to US\$1.00, the effective noon buying rate as of March 31, 2013 in the City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York.

[2] Each ADS represents three ordinary shares of the Company.

[3] Definition of adjusted EBITDA: Adjusted EBITDA is defined as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange gain, loss from disposal of property, plant and equipment and other income or expense.

Concord Medical Services Holdings Co., Ltd. **Consolidated Balance Sheets** (in thousands)

Jumme Jumme <th< th=""><th></th><th rowspan="2">December 31, 2012 (*) RMB</th><th colspan="2">March 31, 2013</th></th<>		December 31, 2012 (*) RMB	March 31, 2013	
SSU-15				•
Zah 75,82 181,511 20,25 Scritter clas, furter perion 280,007 281,000 34,007 Vectors in strowble 76,722 115,300 34,007 Vectors in strowble 76,722 115,300 34,007 Verter last sols, current perion 68,451 114,426 13,350 Vectors in strowble 68,451 114,426 13,350 Vectors in strowble 68,351 114,346 13,350 Vectors in strowble 68,351 114,346 13,350 Vectors in strowble 68,351 114,346 13,350 Vectors in strowble 61,353 13,017 13,350 Vectors in strowble 13,030 14,641 13,350 Vectors in strowble 14,578 22,257 33,860 14,571 Vectors in strowble 10,013 14,270 14,830 14,490 Vectors in strowble 114,758 22,257 33,86 14,571 Vectors in strowble 114,758 14,270 14,350 14,490	ASSETS		(Onddanced)	(Onuduricu)
sectional cash, runner portion 284,047 284,007 216,039 34,389 nerrentive 8,841 11,179 1,345 nerrentives 8,841 11,426 13,355 nerrentives 8,841 11,426 13,355 Section Cast assets, current portion 10,053 15,107 11,305 Deferred tas assets, current portion 10,000 9,3410 13,000 nates assets, current portion 11,200 1,446 233 Non-current assets 11,200 1,446 233 Non-current assets 11,200 1,446 233 Non-current asset 11,200 1,446 233 Social and equipment, set 12,22,285 41,513 13,511 2,707 Non-current asset 144,513 13,513 2,707 13,548 144,513 13,513 2,709 24,442 14,353 144,353 144,353 144,353 144,353 144,353 144,353 144,353 144,353 144,353 144,353 143,353 144,353 <td< td=""><td>Current assets</td><td></td><td></td><td></td></td<>	Current assets			
kcounts needbale 210,207 216,500 34,800 Vergament and other current assets 67,472 115,301 113,501 Vergament and other current assets 67,472 115,301 113,501 Vergament assets 67,472 115,301 113,501 Schurd tas sets, corrent periton 100,000 03,340 116,000 Schurd tas sets, corrent assets 65,313 109,3290 42,047 Schurd and Steppmenn, net 1,22,930 22,020 42,047 Sprange and Steppmenn, net 1,22,930 22,020 42,047 Sprange and Steppmenn, net 1,22,930 23,010 72,331 Sprange and Steppmenn, net 1,22,930 23,010 72,331 Sprange and Steppmenn, net 1,22,930 40,641 13,340 Sprange and Steppmenn, net 1,22,930 24,044 14,340 14,340 Sprange and Steppmenn, net 1,22,571 33,860 14,330 14,340 14,340 14,340 14,340 14,340 14,340 14,340 14,340 14,340 14,340	Cash			
newnories 0.681 12.079 1.945 Yeapynness and only curven asses 0.7472 115.399 1.945 Yeapynness and only curven asses 0.8451 114.245 118.385 Stran a noncompany only polition 1.0000 1.3411 1.559 Name at the from related parties 0.3512 1.662 223 Strat at the from related parties 0.3513 1.623 1.662 226 226 226 226 1.672 235 236 246 1.150 236 246 1.150 236 246 1.151 236 236 246 1.151 236 236 246 1.151 236 236 246 1.151 236 236 246 1.151 237 33586 246 236	Restricted cash, current portion	- /-	-)	45,727
inpagements and other current assets 67,72 115,09 115,06 Versiventsents inforter financing locase, current proton 16,03 114,246 113,00 Deferred tas tasts, current proton 10,00 14,464 123,00 Name the from versivents 853,13 1,000,01 14,464 123,00 Name the from versivent assets 853,13 1,000,01,01 44,464 123,00 44,464 123,00 44,464 123,00 44,464 123,00 44,464 123,00 44,464 123,00 44,164 123,00 44,164 123,00 44,164 123,00 44,161 14,161 16,111 12,017 133,00 44,164 123,00 44,161 12,017 133,00 14,161 16,111 2,217,07 13,866 133,00 13,00 13,00 13,00 13,00 13,00 13,00 14,409 14,409 14,409 14,409 14,409 14,409 14,409 14,409 14,409 14,409 14,409 14,409 14,403 14,409 14,403 14,409	Accounts receivable			
Scribberg 88,451 114,246 18,385 Octered tax assets, current portion 10,633 19,617 31,395 Can to a subsidiary 10,000 9,410 15,003 Data to a subsidiary 10,000 9,410 15,003 Data to arrent assets 83,133 100,000 9,410 15,003 Data to arrent assets 152,22,00 1,30,599 24,64,52 20,805 42,512 Scrib to arrent assets 164,512 188,500 22,313 22,313 22,313 22,313 22,313 22,313 22,313 22,313 22,313 23,310 37,513 31,66 31,67 31,66 31,66 31,66 31,66 31,66 31,66 31,66 31,66 31,66 31,66 31,66 31,66 </td <td></td> <td></td> <td></td> <td></td>				
befered ax asses, current portion 16,693 19,617 31,89 before dax asses, current portion 100000 93,410 15,840 bala current asses 1200 1,446 233 bala current asses 122,920 1,530,599 246,642 control asses 122,920 1,530,599 246,642 control asses 122,920 1,530,599 246,642 control asses 124,512 138,570 223,835 by position non-current assets 146,512 138,570 223,831 by position non-current assets 114,758 114,330 138,440 by position non-current assets 041,778 114,330 138,440 by paid land lesse provemants 041,778 041,330 138,440 by paid land lesse provemants 041,778 043,330 164,443,870 by paid land lesse provemants 041,772 249,475 043,330 by paid land lesse provemants 041,773 042,455 043,331,40 06,689 contravert assets 041,773 043,935 04				
.can to annocarroling skenholder of a subsidiary 10,000 93,410 13,400 Narout dre form (artel parties) 1200 1,446 233 Narout dre form (artel parties) 120,200 1,35,500 246,422 Nongrith (artel parties) 120,200 1,35,500 224,711 Nongrith (artel parties) 162,938 90,406 1,45,510 223,771 Stand (arter) family (later) famic (later) f				
Anound before related parties 1,200 1,446 233 Name and equipment, net 1,252,200 1,533,599 246,442 CondWill 222,085 222,085 47,157 Stratt and equipment, net 16,521,63 196,040 222,085 47,157 Stratt and equipment, net in sets 16,521,63 196,040 222,577 35,366 Verter dux assets, non-current portion 111,178 111,330 118,430 18,433 18,443 14,439 18,453 19,353 13,632,531 13,64,64 16,553 16,653 16,653 16,653 16,653 16,653 16,653 16,653 <td></td> <td></td> <td></td> <td></td>				
Ibal curver asset 153,130 1,128,110 1,128,110 1,127,170 Non-curver asset 1,222,200 1,330,599 246,412 242,485 421,513 1,330,599 246,412 mangple save, net 1,222,800 1,253,659 222,885 421,513 1,253,757 3,536,65 Net inserts in the rests 1,253,65 222,825 223,559 233,513 3,353,100 3,75,513 Solver assets, onc-current portion 1,14,738 114,330 18,440 14,441 14,443 14,443 14,443 14,443 14,443 14,441 14,443 14,443				
Numer and assets				
'popers, plant and equipment, net 1,522,200 1,532,530 222,885 47,157 intangible saset, net 146,512 133,570 22,313 inter, financing lease, non-current assets 146,512 133,570 22,313 inter, financing lease, non-current assets 171,545 222,751 13,360 inter, financing lease, non-current assets 144,758 114,350 114,350 114,350 inter, manufacturent assets 61,706 61,706 93353 inter non-current assets 2,812,407 2,790,745 448,3327 inter non-current assets 2,812,407 2,790,745 448,3337 inter numblified 3,665,220 3,829,055 616,516 LABL LITLES AND EQUITY 101,473 245,51 30,661 LABL Company 100,653 116,453 </td <td></td> <td>853,133</td> <td>1,038,310</td> <td>167,179</td>		853,133	1,038,310	167,179
isodovili 292,885 292,885 292,885 292,885 292,885 242,817 brangble asset, and 165,512 138,570 22,311 22,357 23,865 befered ax assets, non-current portion 171,545 22,2757 35,866 23,9100 37,353 befered ax assets, non-current portion 18,110 16,911 2,707 38,866 33,931 38,941 14,409 34,943 14,409 34,943 14,409 36,952,20 3,929,955 64,9337 36,952,20 3,929,955 64,9337 36,952,20 3,929,955 64,9337 36,91,96 9,935 16,93 36,91 61,956 3,935 16,91,95 39,935 16,93 36,91 61,699 36,91 16,93 36,91 61,699 36,91 16,93 36,91 61,699 31,91 13,93 38,140 61,699 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 36,91 <td></td> <td></td> <td></td> <td></td>				
ninagbine seer, net 146,512 118,570 22.311 popsis for non-current portion 171,545 222,577 35.866 elterrel ata sets, non-current portion 18,110 16,211 2,757 35.866 elterrel ata sets, non-current portion 230,558 233,100 37.331 Signity method investments 230,558 233,100 37.331 Signity method investments 240,558 233,000 37.331 Signity method investments 61,706 61,706 9.9355 Total assets 2412,087 2490,275 449.337 Total assets 38.083 33.140 35.061 LABELTITES AND EQUITY 2.117 1.125 19.073 33.061 30.063 15.6351 LABELTITES AND EQUITY 2.242 33.043 35.061 30.063 15.700 Larget mabals borrowings 19.473 345.451 30.661 30.663 15.700 Larget mabals Gautament borrowings 131.473 30.461 50.163 15.700 10.933 31.643 30.				- /
3pensits for non-current assets 162,338 90.496 14,571 Winsestments in direct financing lases, non-current portion 171,545 222,757 358,66 Deferse tax assets, non-current portion 18,110 16,631 22,707 gaity method investments 230,558 233,100 373,531 Dher non-current assets 61,705 61,705 61,705 Drad non-current assets 2,812,607 2,290,225 449,332 Total non-current assets 2,812,607 2,290,225 449,332 Total non-current assets 3,665,220 3,829,455 493,304 Ontal non-current assets 2,812,607 2,290,225 449,332 Total non-current assets 3,831,40 61,605 61,705 53,806 Accounts payable 191,473 245,551 39,801 34,804 18,748 Current tabilities 191,473 245,551 39,801 34,804 18,748 Current reportion 2,117 1,225 19,701 34,804 54,551 Curouts expenses and other liabilities <t< td=""><td></td><td></td><td></td><td></td></t<>				
Nei investiments in direct financing lesses, non-current portion 11,1545 222,757 32,866 Deterned tax sests, non-current portion 18,110 16,811 2,707 Sputy method investments, non-current portion 230,898 233,100 37,531 Deterned tax sests, non-current assets 90,124 89,491 14,303 18,408 Prepaid land lesse payments 61,706 61,706 61,706 9,335 Total non-current assets 2,812,087 2,790,745 449,337 Total assets 36,65,220 3,823,040 61,65.56 LABLITIES AND EQUITY				/-
Deferred tax assets, non-current portion 18,10 16,811 2,707 printy method investments 230,589 233,100 37,351 Dher non-current assets 01,124 88,491 14,4309 ndeminification assets 61,706 61,706 9,935 foral assets 2,802,072 449337 144337 foral assets 3,665,220 3,829,055 616,516 LABILITES AND EQUITY				
Squity method investments 220.500 233,100 37,531 Deter non-current assets 90,124 89,491 14,430 hemainfication assets 61,706 61,706 61,706 ford non-current assets 2,812,087 2,799,745 4493,337 ford assets 3,665,220 3,829,055 616,516 LABLLTES AND EQUTY 3 33,040 61,689 Sub-term bank borrowings, current portion 191,473 245,551 39,001 Counts payhe 100,663 116,443 18,748 Current bank borrowings, current portion 2,117 1,225 197 Current payable 20,404 99,069 15,700 Oracine tax payable 2,433 19,766 3,183 Cele capenese and other liabilities 5,510 8,311 1,338 Cele capenese and other liabilities 2,243 19,766 3,183 Cele capenese and other liabilities 3,510 8,311 1,338 Cele capenese and other liabilities 5,510 8,311 1,338 C				
Dhe'nonc-urrent assets 114,738 114,330 18,488 Memification assets 61,706 61,706 9.935 Total assets 2,812,087 2,493,297 2,493,297 2,493,297 5,493,397 5,615,516 LABLITTES AND EQUTY				
speak 90,124 80,491 14,409 nemmification assets 2,012,007 2,209,745 449,337 foral assets 3,665,220 3,629,055 616,516 LABLLTES AND EQUITY 3 381,003 383,140 616,809 Sum-tern bank borrowings, current portion 191,473 245,951 39,601 Corounts payable 100,563 116,443 181,8748 Accounts payable 20,117 1,225 197 Accounts payable 22,117 1,225 197 Accounts payable 22,433 19,768 3,183 Orient exer payable 22,433 19,768 3,183 Orient exer payable 22,443 19,768 3,183 Oried aurrent biblities, current portion 5,910 8,311 1,338 Deferred tax labilities, current portion 5,910 8,311 1,338 Oried aurrent biblities, current portion 6,50,533 9,664,25 149,228 Oried aurrent biblities, current portion 6,50,53 9,662,5 149,228				
ndeminication asseris 61,06 61,06 9.935 Total anocurrent assets 2.812,087 2.790,745 449.337 Total asseris 3.666,220 3.829,055 616,516 LABLITTES AND FOUTY 381,063 383,140 61,689 Jorrent labilities 983,063 383,140 61,689 Jorgeterm bank hourovings, current portion 191,473 245,951 39,061 Accent payable 100,563 116,443 188,748 Accent payable 2,117 1,225 197 Accent ex payable 2,243 19,768 3,183 Defined rotencurrent controin 18,875 19,369 3,183 Accent de parties, current portion 2,243 19,768 3,183 Accent de parties, current portion 5,910 8,311 1,338 Accent de parties, current portion 2,249 3,346 5,357 Total concurrent Labilities 300,901 32,295 5,290 Anourd due to related parties, non-current portion 37,719 67,719 67,719				
Intel non-current assets 2.812.087 2.790.745 449.337 Fand assets 3.665.20 3.82.055 616.516 LABLITIES AND EQUITY				
Interface 3,665.220 3,829,055 616.516 LABLITTES AND EQUITY				
LABLITTES AND EQUITY		· · · · · ·		
Current Liabilities 383,083 383,140 61,689 Long-term bank borrowings, current portion 191,473 245,951 383,061 Accounts payable 100,563 116,443 187,848 Accounts payable 20,01 31,105 5,018 Diligations under capital leases, current portion 2,117 1,225 197 Accrued expenses and other liabilities 20,040 06,069 31,105 5,018 Accrued expenses and other liabilities, current portion 2,2433 19,708 3,183 Deferred rex luabilities, current portion 2,243 3,344 545 Deferred rex luabilities, current portion 2,248 3,344 545 Deferred rex luabilities, current portion 2,248 3,343 545 Deferred rex luabilities, con-current portion 2,248 3,346 35,357 Deferred rex luabilities, con-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharg, non-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharg, non-current portion	Total assets	3,665,220	3,829,055	616,516
Current Liabilities 383,083 383,140 61,689 Long-term bank borrowings, current portion 191,473 245,951 383,061 Accounts payable 100,563 116,443 187,848 Accounts payable 20,01 31,105 5,018 Diligations under capital leases, current portion 2,117 1,225 197 Accrued expenses and other liabilities 20,040 06,069 31,105 5,018 Accrued expenses and other liabilities, current portion 2,2433 19,708 3,183 Deferred rex luabilities, current portion 2,243 3,344 545 Deferred rex luabilities, current portion 2,248 3,344 545 Deferred rex luabilities, current portion 2,248 3,343 545 Deferred rex luabilities, con-current portion 2,248 3,346 35,357 Deferred rex luabilities, con-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharg, non-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharg, non-current portion	LIABILITIES AND EQUITY			
short-erm bank borrowings_corrent portion 383,083 383,140 61,689 cong-term bank borrowings_corrent portion 191,473 245,951 39,601 Accound for purchase of property, plant and equipment 40,6091 31,165 50,18 Dilgations under capital leases, current portion 2,117 1,225 197 Accrued expenses and other liabilities 22,403 19,768 3,183 Deferred ravenue, current portion 22,433 19,768 3,183 Deferred ravenue, current portion 5,910 8,311 1,338 Deferred tax liabilities, current portion 5,910 8,311 1,338 Petered tax liabilities, current portion 2,02,040 98,0625 149,228 Non-current tabilities 89,0533 92,66,25 149,228 Non-current portion 300,901 382,926 61,655 Carler dax itabilities, onc-current portion 67,719 67,719 10,903 Accrued unrecognized tax benefits & surcharge, non-current portion 35,668 32,255 5,200 Carl anon-current liabilities, ono-current portion 25,6,88				
Accounts payable 100,563 116,443 18,748 Accounts protections of property, plant and equipment 40,691 31,165 5,018 Diligations under capital leases, current portion 2,117 1,225 197 Account synable 92,040 98,069 15,790 Account synable 22,433 19,768 3,183 Deferred revenue, current portion 18,975 19,369 3,113 Deferred revenue, current portion 5,910 8,311 1,338 Deferred tax liabilities, current portion 2,248 3,384 545 Diract current liabilities 859,533 926,825 149,228 Non-current liabilities 859,533 926,825 149,228 Non-current liabilities 859,533 926,825 149,228 Non-current liabilities 300,901 382,926 61,655 Account due to related paries, non-current portion 67,719 67,719 10,903 Other long term liabilities 34,646 33,336 5,355 Fotal non-current liabilities 1,325,810	Short-term bank borrowings	383,083	383,140	61,689
Accounts payable 100,563 116,443 18,748 Accounts payable 40,691 31,165 5,018 Diligations under capial leases, current portion 2,117 1,225 197 Accrued for purchase of property, plant and equipment 92,040 98,069 15,790 Accrued texpenses and other liabilities 22,433 19,768 3,183 Deferred revenue, current portion 18,975 19,369 3,118 Anount due to related parties, current portion 2,248 3,334 5455 Defared tax liabilities, current portion 859,533 926,825 149,228 Non-current liabilities 859,533 926,825 149,228 Non-current liabilities 300,901 382,926 61,655 Cred unercognized tax banefits & surcharge, non-current portion 67,719 67,719 10,903 Other lang term liabilities 34,646 33,336 5,355 Total anon-current liabilities 1325,01 1470,649 236,735 Total anon-current liabilities 105 105 17 Cothal liabilities<	Long-term bank borrowings, current portion	191,473	245,951	39,601
Diligations inder capital leases, current portion 2,117 1,225 197 Accrued expenses and other liabilities 92,040 98,069 15,303 norme tax payable 22,433 19,768 3,183 Deferred revenue, current portion 18,975 19,369 3,119 Noncont text correlated parties, current portion 2,243 3,364 545 Deferred tax liabilities, current portion 2,243 3,384 545 Non-current liabilities 2,243 3,384 545 Non-current liabilities 300,901 382,925 149,228 Non-current liabilities 300,901 382,926 61,655 Accrued unrecognized tax koenefits & surcharge, non-current portion 30,601 32,825 5,290 Deferred tax liabilities 34,646 33,336 5,335 5,290 Fotal non-current liabilities 465,677 543,664 87,335 5,355 Total abilities 105 105 17 Ordia liabilities 105 105 17 Total abilities 105 105 17 Total abilities 105	Accounts payable	100,563	116,443	18,748
Accruet expenses and other liabilities 92,040 98,069 15,790 nrome tax payable 22,433 19,768 3,119 Annount due to related parties, current portion 18,975 19,369 3,113 Annount due to related parties, current portion 2,244 3,344 545 Deferred tex liabilities, current portion 2,244 3,344 545 Deferred tex liabilities, current portion 2,244 3,344 545 Deferred tex liabilities, current portion 2,244 3,344 545 Concurrent liabilities 859,533 926,825 149,228 Von-current liabilities 859,533 926,825 149,228 Concurrent liabilities 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 30,646 33,336 5,250 Deferred tex liabilities, non-current portion 35,683 32,855 5,290 Deferred tex liabilities 13,25,310 1,470,489 236,763 Contal uncortinet barties 105 105 17 Contal uncortinet	Accrual for purchase of property, plant and equipment	40,691	31,165	5,018
ncome tax payable 22,433 19,768 3,183 Deferred revenue, current portion 18,975 19,369 3,119 Amount due to related parties, current portion 2,248 3,384 5455 Defared revenue, current portion 2,248 3,384 5455 Non-current liabilities 859,533 926,825 149,228 Non-current liabilities 300,901 382,926 61,6555 Accrued uncorgonized tax benefits & surcharge, non-current portion 67,719 67,719 10,933 Orle long term liabilities 34,646 33,336 5,367 Amount due to related parties, non current 26,828 4,320 Deferred tax liabilities, non-current portion 36,683 32,2855 5,290 Total non-current liabilities 3,3664 87,335 67,6719 67,019 67,019 Commitments 33,663 32,2855 5,290 5,290 5,290 5,290 Total ano-current liabilities 3,664 37,335 5,357 5,364 87,335 Total ano-current liabilities 1,32	Obligations under capital leases, current portion	2,117	1,225	197
Deferred revenue, current portion 18,975 19,369 3,119 Amount due to related parties, current portion 5,910 8,311 1,338 Deferred tax liabilities, current portion 2,248 3,384 545 Forta current liabilities 859,533 926,6225 149,228 Non-current liabilities 300,901 382,926 61,655 Cong-term bank borrowings, non-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 34,646 33,336 5,537 Aber tor term liabilities 34,646 33,336 5,5290 Deferred tax liabilities, on current 35,683 32,255 5,290 Total non-current liabilities 34,646 33,356 87,535 Total and contingencies 1,325,310 1,470,489 236,763 Commitment sand contingencies 105 105 17 Ordinary shares 105 105 17 Ordinary shares 105 105 17 Ordina	Accrued expenses and other liabilities			15,790
Amound ube to related parties, current portion 5,910 8,311 1,338 Deferred tax liabilities, current portion 2,248 3,384 545 Total current liabilities 859,533 926,825 149,228 Song-term bank borrowings, non-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 109,001 Other tong term liabilities 34,646 33,336 5,367 Amount due to related parties, non current 26,828 4,826 32,855 5,290 Deferred tax liabilities 32,653 32,855 5,290 Defar do non-current portion 35,683 32,855 5,290 Defared tax liabilities 34,646 33,336 53,367 Amount due to related parties, non current 26,828 468,277 543,664 87,535 Dotal liabilities 1,325,310 1,420,489 236,673 20,6763 Commitments and contingencies 105 105 17 EQUITY 105 105 17 Ordiany shares 105 105 17	Income tax payable	22,433	19,768	3,183
Deferred tax liabilities, current portion 2,248 3,384 545 Total current liabilities 859,533 926,825 149,228 Non-current liabilities 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 10,903 Oher long term liabilities 34,646 33,336 5,367 Amount due to related parties, non current 26,828 26,828 4,320 Deferred tax liabilities, non-current portion 35,663 32,855 5,290 Total ano-current liabilities 465,777 543,664 87,535 Total liabilities 1,325,310 1,470,489 236,565 Commitments and contingencies 105 105 17 Prefasury sock (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated deficit (469,055) (149,372) (2,710) Accumulated deficit (469,055) (419,372) (2,710) Noncontrolling interests 308,324 307,681 49,540 Noncontrolling interests 308	Deferred revenue, current portion			
Botal current liabilities 859,533 926,825 149,228 Non-current liabilities 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 10,903 Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 10,903 Amount due to related parties, non current 24,646 33,336 5,363 Ordered tax liabilities, non-current portion 35,683 32,855 5,290 Fotal liabilities, non-current portion 35,683 32,855 5,290 Fotal liabilities, non-current portion 35,683 32,855 5,290 Fotal liabilities 465,777 543,664 87,535 Commitments and contingencies 105 105 17 Prelary shares 105 105 17 Prelary shares (15) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,270 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit	Amount due to related parties, current portion			
Non-current liabilities 300,901 382,926 61,655 cong-term bank borrowings, non-current portion 67,719 67,719 10,903 Other long term liabilities 34,646 33,336 5,367 Ancound due to related parties, non current 26,828 26,828 4,320 Deferred tax liabilities, non-current portion 35,663 32,855 5,290 Total non-current liabilities 465,777 543,664 87,535 Total liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies 105 105 17 Treasury stock (5) (4) (1) Additional paid-in capital 2,517,496 2,510,986 405,260 Accumulated other comprehensive loss (16,555) (16,830) (2,710) Accumulated deficit (49,055) (449,372) (72,353) Total Concord Medical Services Holdings Limited shareholders' equity 308,324 300,681 49,540 Noncontrolling interests 308,324 307,681 49,540 Total liabilities and equity	Deferred tax liabilities, current portion	2,248	3,384	545
Long-term bank borrowings, non-current portion 300,901 382,926 61,655 Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 10,903 Other long term liabilities 34,646 33,336 5,367 Amount due to related parties, non current 26,828 26,828 4,320 Deferred tax liabilities, non-current portion 35,683 32,855 5,290 Fotal liabilities 465,777 543,664 87,535 Fotal liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies 105 105 17 Creating shares 105 105 17 Ordinary shares 105 105 17 Ordinary shares 105 105 17 Ordinary shares 105 16,830 (2,710) Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit 2,031,586 2,050,885 330,213 Fotal liabilities and equity 308,324 307,681 49,540 <td>Total current liabilities</td> <td>859,533</td> <td>926,825</td> <td>149,228</td>	Total current liabilities	859,533	926,825	149,228
Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 10,903 Other long term liabilities 34,646 33,336 5,367 Amount due to related paties, non current 26,828 26,828 4,320 Deferred tax liabilities, non-current portion 35,683 32,855 5,290 Fotal non-current liabilities 465,777 543,664 87,535 Total liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies 105 105 17 Preasury stock 105 105 17 Creasury stock (16,955) (16,830) (2,710) Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Total liabilities and equity 308,324 307,681 49,540 Noncontrolling interests 338,324 307,681 49,540 Total liabilities and equity 3,665,220 3,829,055 616,516	Non-current liabilities			
Accrued unrecognized tax benefits & surcharge, non-current portion 67,719 67,719 10,903 Other long term liabilities 34,646 33,336 5,367 Amount due to related paties, non current 26,828 26,828 4,320 Deferred tax liabilities, non-current portion 35,683 32,855 5,290 Fotal non-current liabilities 465,777 543,664 87,535 Fotal liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies 105 105 17 Preasury stock 105 105 17 Creasury stock 2,517,496 2,516,986 405,201 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Fotal Liabilities and equity 336,8324 307,681 49,540 Noncontrolling interests 338,324 307,681 49,540 Fotal liabilities and equity 3,665,220 3,829,055 616,516	Long-term bank borrowings, non-current portion	300,901	382,926	61,655
Amount due to related parties, non current 26,828 26,828 4,320 Deferred tax liabilities, non-current portion 35,683 32,855 5,290 Data non-current liabilities 465,777 543,664 87,535 Total liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies	Accrued unrecognized tax benefits & surcharge, non-current portion		67,719	10,903
Deferred tax liabilities, non-current portion 35,683 32,855 5,290 Total non-current liabilities 465,777 543,664 87,535 Total liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies 105 105 17 Drefasory stock (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (449,072) (72,353) (72,353) Total Concord Medical Services Holdings Limited shareholders' equity 308,322 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total Liabilities and equity 3,665,220 3,829,055 616,516	Other long term liabilities			
Additional paid-in capital 465,777 543,664 87,535 Total liabilities 1,325,310 1,470,489 236,763 Commitments and contingencies 105 105 17 EQUITY 105 105 17 Treasury storck (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,830) (2,710) Accumulated deficit (449,372) (72,353) Total Concord Medical Services Holdings Limited shareholders' equity 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516	Amount due to related parties, non current	26,828	26,828	
Interview Interview <t< td=""><td>Deferred tax liabilities, non-current portion</td><td>35,683</td><td>32,855</td><td>5,290</td></t<>	Deferred tax liabilities, non-current portion	35,683	32,855	5,290
Commitments and contingencies Image: Commitments and contingencies EQUITY Ordinary shares 105 105 17 Dreasury stock (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516	Total non-current liabilities	465,777	543,664	87,535
Ordinary shares 105 105 17 Ordinary shares (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516	Total liabilities	1,325,310	1,470,489	236,763
Drdinary shares 105 105 17 Treasury stock (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Total Concord Medical Services Holdings Limited shareholders' equity 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516	Commitments and contingencies			
Drdinary shares 105 105 17 Treasury stock (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Total Concord Medical Services Holdings Limited shareholders' equity 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516	EQUITY			
Treasury stock (5) (4) (1) Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Total Concord Medical Services Holdings Limited shareholders' equity 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516		105	105	17
Additional paid-in capital 2,517,496 2,516,986 405,260 Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Noncontrolling interests 308,324 307,681 49,540 Total Concord Medical Services Holdings Limited shareholders' equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516				
Accumulated other comprehensive loss (16,955) (16,830) (2,710) Accumulated deficit (469,055) (449,372) (72,353) Fotal Concord Medical Services Holdings Limited shareholders' equity 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516				
Accumulated deficit (469,055) (449,372) (72,353) Fotal Concord Medical Services Holdings Limited shareholders' equity 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516				
Total Concord Medical Services Holdings Limited shareholders' equity 2,031,586 2,050,885 330,213 Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516	Accumulated deficit			
Noncontrolling interests 308,324 307,681 49,540 Total equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516				
Cotal equity 2,339,910 2,358,566 379,753 Total liabilities and equity 3,665,220 3,829,055 616,516				
Total liabilities and equity 3,665,220 3,829,055 616,516	-			
	10tal labilities and equity (*) Amounts for the year ended December 31, 2012 were derived from the December 31, 2012 audited consolidated financial statements	3,003,220	3,029,033	010,010

Total liabilities and equity
(*)Amounts for the year ended December 31, 2012 were derived from the December 31, 2012 audited consolidated financial statements.

Concord Medical Services Holdings Limited Consolidated Statements of Income (in thousands, except per ADS data)

March 31, 2012 (*) March 31, 2012 (*) March 31, 2012 (*) RMB RMB RMB Revenues, net of business tax, value-added tax and related surcharges (Unaudited) (Unaudited)	h 31, 2013 US\$ (Unaudited)
	(Unaudited)
Revenues, net of business tax, value-added tax and related surcharges (Unaudited) (Unaudited)	
Network 106,731 111,655	17,978
Hospital-Medicine income – 39,760	6,402
Hospital-Medical service income 52,499	8,453
Total net revenues 106,731 203,914	32,833
Cost of revenues	
Network (44,446) (49,844) (8,025)
Hospital-Medicine cost – (33,893) (5,457)
Hospital-Medical service cost (48,704) (7,842)
Total cost of revenues (44,446) (132,441)) (21,324)
Gross profit 62,285 71,473	11,509
Operating expenses	
Selling expenses (7,979) (16,457) (2,650)
General and administrative expenses (16,965) (25,403) (4,090)
Operating income 37,341 29,613	4,769
Interest expenses (3,810) (9,276) (1,494)
Foreign exchange gain, net 60 2	
Loss on disposal of property, plant and equipment (1,396) (110) (18)
Interest income 1,559 5,443	876
Share of net profit of equity investees – 4,238	682
Other (expense) income, net7 (58) (9)
Income before income taxes 33,761 29,852	4,806
Income tax expenses (8,773) (10,812) (1,741)
Net income 24,988 19,040	
Net (loss) income attributable to noncontrolling interests 809 (643)) (104)
Net income attributable to ordinary shareholders24,17919,683	3,169
Earnings per ADS	
Basic /Diluted 0.52 0.44	0.07
Weighted average number of ADS outstanding:	
Basic /Diluted 46,849,399 45,098,232	45,098,232
Other comprehensive income, net of tax	
Foreign currency translation 28 125	20
Total other comprehensive income, net of tax28125	20
Comprehensive income 25,016 19,165	3,085
Comprehensive income (loss) attributable to noncontrolling interests 809 (643) (104)
Comprehensive income attributable to Concord Medical Services Holdings Limited's shareholders 24,207 19,808	3,189

(*) Certain amounts in the prior year quarterly financial information are being reclassified for comparison purposes.

Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures (*) (in RMB thousands, unaudited)

	For the three months ended March 31, 2012			For the three months ended March 31, 2013		
	GAAP Measure	Adjustment	Non-GAAP Measure	GAAP Measure	Adjustment	Non-GAAP Measure
Operating income	37,341	2,271	39,612	29,613	2,244	31,857
Net income	24,988	2,271	27,259	19,040	2,244	21,284
Basic earnings per ADS	0.52	0.05	0.57	0.44	0.05	0.49
Diluted earnings per ADS	0.52	0.05	0.57	0.44	0.05	0.49

(*) The only adjustment is share-based compensation.

Reconciliation from net income to adjusted EBITDA(*) (in RMB thousands, unaudited)

	For the three months ended March 31, 2012	For the three months ended March 31, 2013
Net income	24,988	19,040
Interest expenses, net	2,251	9,276
Income tax expenses	8,773	10,812
Depreciation and amortization	33,964	47,473
Share-based compensation	2,271	2,244
Other adjustments	1,329	166
Adjusted EBITDA	73,576	89,011

(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange gain, loss from disposal of property, plant and equipment and other income or expense.